References Introduced During IPR Proceeding Not Necessarily New Evidence to Which Patent Owner Had No Opportunity to Respond

May 23, 2018

Reading Time : 2 min

The IPR petition alleged that the claim would have been obvious in light of the combination of two references: Austin and Brehove. Austin teaches the use of oxaboroles as fungicides and discloses that tavaborole inhibits a variety of fungi, including C. albicans. Brehove teaches that use of similar types of compounds to treat onchomycosis and discloses the results of in vivo testing of two such compounds where a patient’s onchomycosis was successfully treated. The Board concluded that a person of ordinary skill in the art would have expected that tavaborole, which shares functional activity with the Brehove compounds against C. albicans, would also have functional activity against other fungi responsible for onchomycosis (like dermatophytes), and would have combined Austin with Brehove with a reasonable expectation of success.

In reaching its conclusion, the Board cited evidence from three additional articles: Nimura, Segal and Mertin. On appeal, Anacor argued that the Board improperly relied on Segal and Mertin, which was new evidence not cited in the petition and to which Anacor did not have an opportunity to respond. The Federal Circuit explained that there is “no blanket prohibition against the introduction of new evidence,” which is “to be expected” during an IPR proceeding, so long as the opposing party has notice and an opportunity to respond. Moreover, a petitioner may introduce new evidence in reply to the patent owner’s evidence, or to document “the knowledge that skilled artisans would bring to bear” in the analysis.

Here, Anacor had notice and several opportunities to respond to both references. Anacor spent three pages of its patent owner’s response discussing Segal. Mertin was the third article in a series of three. Anacor’s expert, Dr. Lane, relied on the first two Mertin articles in her declaration. When cross-examined about the third Mertin article, Dr. Lane admitted that she was familiar with it. The third Mertin article was used again at the deposition of another Anacor expert and was discussed extensively by Anacor at the hearing before the Board. The Federal Circuit concluded that “Anacor had ample notice of and an opportunity to respond to the Segal and Mertin references, which in any event were properly offered in reply to arguments made by Anacor and for the purpose of showing the state of the art at the time of the patent application.” Accordingly, Anacor had not been denied its procedural rights.

Anacor Pharms., Inc. v. Iancu, No. 17-1947 (Fed. Cir. May 14, 2018)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.